A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China

The Expand Access Program (EAP) of Iressa(gefitinib, ZD1839) in China was initiated in 2001 with the aim of providing gefitinib to non-small cell lung cancer (NSCLC) patients who failed to respond to standard treatment or who could not tolerate chemotherapy. The primary objective was to describe the...

Full description

Saved in:

Bibliographic Details
Published in:	Zhongguo fei ai za zhi Vol. 15; no. 6; pp. 332 - 339
Main Authors:	Li, Longyun, Zhong, Wei, Liao, Meilin, Chen, Li, Han, Baohui, Guan, Zhongzhen, Yu, Shiying, Liu, Xuyi, Wu, Yilong, Jiang, Guoliang, Xu, Jianming, Chen, Jia, Tao, Min, Luo, Rongcheng, Li, Weimin, Xu, Nong, Zhao, Xiao, Wang, Mengzhao
Format:	Journal Article
Language:	Chinese
Published:	China Chinese Anti-Cancer Association Chinese Antituberculosis Association 01-06-2012 Chinese Anti-Cancer Association; Chinese Antituberculosis Association
Subjects:	Aged Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer therapies Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Chemotherapy China Cross-Sectional Studies Epidermal growth factor Expand Access Program (EAP) Female Gefitinib Genotype Hospitals Humans Long-term survival Lung cancer Lung neoplasms Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Lung Neoplasms - genetics Male Medical prognosis Middle Aged Mutation Oncology Prognosis Public Health Practice - statistics & numerical data Quality of Life Quinazolines - adverse effects Quinazolines - therapeutic use Respiratory diseases Retrospective Studies Safety Survivors - statistics & numerical data Time Factors Treatment Outcome China Beijing China
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!